学名药市场规模、份额、成长分析（按给药途径、按治疗用途、按剂型、按分销管道、按最终用户、按地区）－2025-2032 年产业预测

2023 年全球学名药市场规模价值 4,872.1 亿美元，预计将从 2024 年的 5,130.3 亿美元成长到 2032 年的 7,754.8 亿美元，预测期内（2025-2032 年）的复合年增长率为 5.3%。

受慢性病发病率上升和对具有成本效益的药物选择的需求推动，学名药市场正在经历显着增长。学名药（ 学名药 ）具有与品牌药相同的化学成分，但价格较低，在新兴经济体和已开发经济体中越来越受欢迎。 FDA 专利保护为品牌药物开发商提供了暂时的独占权，以防止学名药竞争。然而，一旦专利到期，学名药可以透过快速核准程序迅速进入市场，同时遵守严格的品质、安全和功效标准。高价值药物专利到期进一步推动了这一趋势，促进了学名药的开发和供应，从而支持了市场扩张。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 二次资料和一次资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分机会分析

市场动态与展望

• 市场概览
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

关键市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024年）
• PESTEL分析
• 总体经济指标
• 价值链分析
• 定价分析
• 案例研究
• 监管格局
• 客户和购买标准分析

学名药市场规模（按给药途径和复合年增长率） (2025-2032)

• 市场概览
• 口服
• 肠外
• 局部的
• 吸入
• 经皮
• 眼科
• 其他的

学名药市场规模（依治疗用途和复合年增长率） (2025-2032)

• 市场概览
• 心血管疾病
• 中枢神经系统 (CNS) 疾病
• 感染疾病
• 肿瘤学
• 呼吸系统疾病
• 胃肠道疾病
• 内分泌失调
• 其他的

学名药市场规模（按剂型划分）及复合年增长率（2025-2032）

• 市场概览
• 固态剂型
• 液体剂型
• 半固态形式
• 气体形式

学名药市场规模（依分销管道划分）及复合年增长率（2025-2032）

• 市场概览
• 医院药房
• 零售药局
• 网路药局
• 药局
• 批发商和经销商

学名药市场规模（按最终用户和复合年增长率） (2025-2032)

• 市场概览
• 医院
• 诊所
• 居家照护环境
• 门诊手术中心（ASC）
• 零售消费者

学名药市场规模（按地区）及复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市场占有率分析（2024年）
• 主要企业简介
  • 公司详情
  • 产品系列分析
  • 公司分部份额分析
  • 收益与前一年同期比较对比（2022-2024 年）

主要企业简介

• Sandoz-Switzerland
• Teva Pharmaceuticals-Israel
• Sun Pharmaceutical Industries Ltd.-India
• Viatris Inc.-USA
• Fresenius Kabi AG-Germany
• Cipla Ltd.-India
• Dr. Reddy's Laboratories Ltd.-India
• Lupin Limited-India
• Aspen Pharmacare Holdings Limited-South Africa
• Zydus Cadila-India
• KRKA dd-Slovenia
• Towa Pharmaceutical Co., Ltd.-Japan
• STADA Arzneimittel AG-Germany
• Glenmark Pharmaceuticals Ltd.-India
• Amneal Pharmaceuticals, Inc.-USA
• Biocon Limited-India
• Aurobindo Pharma Ltd.-India
• Sawai Pharmaceutical Co., Ltd.-Japan
• Torrent Pharmaceuticals Ltd.-India
• Hikma Pharmaceuticals PLC-UK

结论和建议

Global Generic Drugs Market size was valued at USD 487.21 billion in 2023 and is poised to grow from USD 513.03 billion in 2024 to USD 775.48 billion by 2032, growing at a CAGR of 5.3% during the forecast period (2025-2032).

The generic drug market is experiencing significant growth, driven by the rising prevalence of chronic diseases and the demand for cost-effective medication options. Generic drugs, which share the same chemical composition as their branded counterparts but are available at lower prices, are gaining traction in both developing and developed economies. The patent protection granted by the FDA gives branded drug developers a temporary monopoly, preventing generic competition. However, once patents expire, generic drugs can swiftly enter the market through expedited approval processes while adhering to stringent quality, safety, and efficiency standards. This trend is further fueled by the expiration of patents for high-value medications, leading to an increase in the development and accessibility of generic alternatives, bolstering market expansion.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Generic Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Generic Drugs Market Segments Analysis

Global Generic Drugs Market is segmented by Route of Administration, Therapeutic Application, Formulation, Distribution Channel, End User and region. Based on Route of Administration, the market is segmented into Oral, Parenteral, Topical, Inhalation, Transdermal, Ophthalmic and Others. Based on Therapeutic Application, the market is segmented into Cardiovascular Disorders, Central Nervous System (CNS) Disorders, Infectious Diseases, Oncology, Respiratory Diseases, Gastrointestinal Disorders, Endocrine Disorders and Others. Based on Formulation, the market is segmented into Solid Dosage Forms, Liquid Dosage Forms, Semi-solid Forms and Gaseous Forms. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Drug Stores and Wholesalers & Distributors. Based on End User, the market is segmented into Hospitals, Clinics, Homecare Settings, Ambulatory Surgical Centers (ASCs) and Retail Consumers. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Generic Drugs Market

The Global Generic Drugs market is significantly driven by the rising prevalence of chronic illnesses, which continues to escalate with the growing aging population. As recorded in 2021, there were over 10.1 million cancer cases in men and 9.3 million in women, alongside more than 350 million individuals diagnosed with arthritis worldwide. This increasing burden of chronic diseases necessitates improved health services, thereby fueling the demand for affordable and accessible healthcare solutions. Consequently, the generic drugs market is anticipated to experience substantial growth throughout the forecast period, as healthcare systems strive to meet the evolving needs of patients.

Restraints in the Global Generic Drugs Market

A significant obstacle hindering the expansion of the global generic drugs market is the stringent regulatory framework imposed by authorities such as the FDA. This agency meticulously assesses the accuracy, potential side effects, and compositional integrity of generic medications. Should manufacturers fail to adhere to these strict standards, they are compelled to withdraw their products from the market. Consequently, the necessity for regulatory approval for generic pharmaceuticals can create delays and complications, ultimately impacting market growth projections. This regulatory environment poses a challenge for manufacturers striving to introduce new generic drugs, thus limiting the overall development of the sector.

Market Trends of the Global Generic Drugs Market

The Global Generic Drugs market is witnessing significant growth, driven by the robust production and consumption of generics in India, which ranks as the third largest pharmaceutical market by volume and fourteenth by value. With over 3,000 pharmaceutical companies and more than 10,500 factories, India is a key player, offering a diverse range of generic drugs. The country is recognized for having the highest number of US-FDA approved manufacturing plants outside the United States, further bolstering its global position. This trend indicates a growing reliance on affordable medications, positioning India as a pivotal hub in the global pharmaceuticals landscape.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Regulatory Landscape
• Customer & Buying Criteria Analysis

Global Generic Drugs Market Size by Route of Administration & CAGR (2025-2032)

• Market Overview
• Oral
• Parenteral
• Topical
• Inhalation
• Transdermal
• Ophthalmic
• Others

Global Generic Drugs Market Size by Therapeutic Application & CAGR (2025-2032)

• Market Overview
• Cardiovascular Disorders
• Central Nervous System (CNS) Disorders
• Infectious Diseases
• Oncology
• Respiratory Diseases
• Gastrointestinal Disorders
• Endocrine Disorders
• Others

Global Generic Drugs Market Size by Formulation & CAGR (2025-2032)

• Market Overview
• Solid Dosage Forms
• Liquid Dosage Forms
• Semi-solid Forms
• Gaseous Forms

Global Generic Drugs Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Drug Stores
• Wholesalers & Distributors

Global Generic Drugs Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospitals
• Clinics
• Homecare Settings
• Ambulatory Surgical Centers (ASCs)
• Retail Consumers

Global Generic Drugs Market Size & CAGR (2025-2032)

• North America (Route of Administration, Therapeutic Application, Formulation, Distribution Channel, End User)
  • US
  • Canada
• Europe (Route of Administration, Therapeutic Application, Formulation, Distribution Channel, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Route of Administration, Therapeutic Application, Formulation, Distribution Channel, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Route of Administration, Therapeutic Application, Formulation, Distribution Channel, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Route of Administration, Therapeutic Application, Formulation, Distribution Channel, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Sandoz - Switzerland
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceuticals - Israel
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. - India
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viatris Inc. - USA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fresenius Kabi AG - Germany
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Ltd. - India
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories Ltd. - India
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin Limited - India
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aspen Pharmacare Holdings Limited - South Africa
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zydus Cadila - India
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• KRKA d.d. - Slovenia
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Towa Pharmaceutical Co., Ltd. - Japan
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• STADA Arzneimittel AG - Germany
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Glenmark Pharmaceuticals Ltd. - India
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amneal Pharmaceuticals, Inc. - USA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biocon Limited - India
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aurobindo Pharma Ltd. - India
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sawai Pharmaceutical Co., Ltd. - Japan
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Torrent Pharmaceuticals Ltd. - India
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hikma Pharmaceuticals PLC - UK
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations